
Indian Patent Office Rejects TB Drug Patent, Boosting Push For Affordable MDR-TB Treatment
The story in brief
The Indian Patent Office rejected a patent for the BPaL regimen, used to treat drug-resistant TB, citing lack of novelty and failure to meet requirements. Mumbai's 4,080 drug-resistant TB cases in 2025 underscore the need for affordable treatment. Activists welcomed the decision, calling access to life-saving medicines a right.